Supernus Pharmaceuticals Equity 2024

Supernus Pharmaceuticals Aktienanalyse

What does Supernus Pharmaceuticals do?

Supernus Pharmaceuticals Inc is an American company specializing in the development, manufacturing, and marketing of pharmaceuticals. The company was founded in 2005 and is headquartered in Rockville, Maryland. Initially, Supernus Pharmaceuticals focused on developing medications for neurological disorders such as epilepsy and ADHD. However, the company has since expanded into other areas of indication such as migraine and Parkinson's disease. The top products of Supernus Pharmaceuticals are the two epilepsy medications, Oxtellar XR and Trokendi XR, both based on a patented technology called "Troxerutin Enriched Osmotic Delivery System" (TREOS). This technology allows for timed release of the active ingredient, resulting in longer duration of action and improved tolerability. Both products are approved in the United States and have proven to be effective and well-tolerated. In addition to Oxtellar XR and Trokendi XR, Supernus Pharmaceuticals has launched other products on the market, including XADAGO for the treatment of Parkinson's disease and Qudexy XR for the treatment of migraine. The company also has a number of compounds in the pipeline currently in various stages of development. The business model of Supernus Pharmaceuticals is based on the development of proprietary technologies and the marketing of novel pharmaceuticals. The company works closely with industry and scientific partners to find innovative solutions to medical challenges. For Supernus Pharmaceuticals, quality is a central component of its business model. The company adheres to strict regulatory requirements and employs modern manufacturing techniques to ensure the highest standards in pharmaceutical production. Additionally, the company maintains close relationships with healthcare providers and patient organizations to ensure that its products meet the needs of patients. Supernus Pharmaceuticals also pursues a robust growth strategy based on exploring new markets and expanding its product portfolio. The company aims to expand its pipeline and develop new technologies to improve the treatment of neurological disorders and promote patient health worldwide. Overall, Supernus Pharmaceuticals is an innovative company distinguished by its commitment to quality and focus on novel solutions in the pharmaceutical industry. The company has established itself as a leading provider of medications for neurological disorders and strives to expand its position in this growing market. Supernus Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Supernus Pharmaceuticals's Equity

Supernus Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Supernus Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Supernus Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Supernus Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Supernus Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Supernus Pharmaceuticals stock

What is the equity of Supernus Pharmaceuticals this year?

Supernus Pharmaceuticals has equity of 921.52 M USD this year.

What was the equity of Supernus Pharmaceuticals compared to the previous year?

The equity of Supernus Pharmaceuticals has increased/decreased by 3.99% increased compared to the previous year.

What impact does a high equity have on investors of Supernus Pharmaceuticals?

A high equity is advantageous for investors of Supernus Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Supernus Pharmaceuticals?

A low equity can be a risk for investors of Supernus Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Supernus Pharmaceuticals affect the company?

An increase in equity of Supernus Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Supernus Pharmaceuticals affect the company?

A reduction in equity of Supernus Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Supernus Pharmaceuticals?

Some factors that can affect the equity of Supernus Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Supernus Pharmaceuticals so important for investors?

The equity of Supernus Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Supernus Pharmaceuticals take to change the equity?

To change equity, Supernus Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Supernus Pharmaceuticals pay?

Over the past 12 months, Supernus Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Supernus Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Supernus Pharmaceuticals?

The current dividend yield of Supernus Pharmaceuticals is .

When does Supernus Pharmaceuticals pay dividends?

Supernus Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Supernus Pharmaceuticals?

Supernus Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Supernus Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Supernus Pharmaceuticals located?

Supernus Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Supernus Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Supernus Pharmaceuticals from 8/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.

When did Supernus Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/24/2024.

What was the dividend of Supernus Pharmaceuticals in the year 2023?

In the year 2023, Supernus Pharmaceuticals distributed 0 USD as dividends.

In which currency does Supernus Pharmaceuticals pay out the dividend?

The dividends of Supernus Pharmaceuticals are distributed in USD.